Hematocrit levels and hospitalization risks in hemodialysis patients.
暂无分享,去创建一个
A. Collins | J. Ebben | Jennie Z. Ma | J. Ma | H Xia | J Ebben | J Z Ma | A J Collins | Hong Xia | H. Xia
[1] L. Hymes,et al. Impaired response to recombinant human erythropoietin therapy in children with peritonitis , 1994 .
[2] J. Adamson,et al. The anemia of chronic disorders: studies of marrow regulation and iron metabolism , 1975 .
[3] R Brookmeyer,et al. Biases in prevalent cohorts. , 1987, Biometrics.
[4] W. Hörl,et al. Neutrophil impairment associated with iron therapy in hemodialysis patients with functional iron deficiency. , 1998, Journal of the American Society of Nephrology : JASN.
[5] A. Collins,et al. Hematocrit level and associated mortality in hemodialysis patients. , 1999, Journal of the American Society of Nephrology : JASN.
[6] D. Cox. Regression Models and Life-Tables , 1972 .
[7] C. Chan,et al. Influence of thalassemia on the response to recombinant human erythropoietin in dialysis patients. , 1993, American journal of nephrology.
[8] M. Siimes,et al. Factors limiting the erythropoietin response in rapidly growing infants with congenital nephrosis on a peritoneal dialysis regimen after nephrectomy. , 1992, The Journal of pediatrics.
[9] C. Le,et al. Prognostic factors, models and related statistical problems in the survival of endstage renal disease patients on hemodialysis. , 1986, Statistics in medicine.
[10] M. Raftery,et al. Increased erythropoietin requirements in patients with failed renal transplants returning to a dialysis programme. , 1994, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[11] B. Pereira,et al. Hematocrit Level Associated Mortality in Hemodialysis Patients, by Ma JZ, Ebben J, Xia H, Collins AJ. J Am Soc Nephrol 10:610–619, 1999 , 2000, Seminars in dialysis.
[12] M. Sandra Wood,et al. Health care financing administration , 2000 .
[13] J. Adamson,et al. Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. Results of a combined phase I and II clinical trial. , 1987, The New England journal of medicine.
[14] W. Owen,et al. Anemia in hemodialysis patients: variables affecting this outcome predictor. , 1997, Journal of the American Society of Nephrology : JASN.
[15] J. Adamson,et al. Management of the anaemia of chronic renal failure with recombinant erythropoietin. , 1989, The Quarterly journal of medicine.
[16] Niels Keiding,et al. Statistical Models Based on Counting Processes , 1993 .
[17] K. Lai,et al. Use of recombinant erythropoietin in thalassemic patients on dialysis. , 1992, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[18] D. Rao,et al. Effect of serum parathyroid hormone and bone marrow fibrosis on the response to erythropoietin in uremia. , 1993, New England Journal of Medicine.
[19] J. Feehally,et al. Effect of recombinant human erythropoietin on erythropoiesis in homozygous sickle-cell anaemia and renal failure. , 1992, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[20] A. Collins,et al. Dialysis unit and patient characteristics associated with reuse practices and mortality: 1989-1993. , 1998, Journal of the American Society of Nephrology : JASN.
[21] D. Churchill,et al. Effect of recombinant human erythropoietin on hospitalization of hemodialysis patients. , 1995, Clinical nephrology.
[22] N. Muirhead,et al. Occult infection and resistance of anaemia to rHuEpo therapy in renal failure. , 1990, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.